Sarepta Therapeutics (NASDAQ:SRPT) Sets New 1-Year Low - Here's What Happened

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) shares reached a new 52-week low during trading on Tuesday . The company traded as low as $101.15 and last traded at $104.81, with a volume of 226454 shares traded. The stock had previously closed at $107.95.

Analysts Set New Price Targets

Several research analysts have recently issued reports on SRPT shares. Guggenheim raised their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Robert W. Baird reduced their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating on the stock in a report on Thursday, November 7th. Piper Sandler lowered their price target on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. Evercore ISI reduced their price objective on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research note on Thursday, November 7th. Finally, Needham & Company LLC restated a "buy" rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a report on Monday, January 27th. One research analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $176.77.

Sarepta Therapeutics Stock Performance

The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock's 50 day moving average price is $117.54 and its 200 day moving average price is $123.61. The company has a market capitalization of $10.15 billion, a price-to-earnings ratio of 85.02 and a beta of 0.75.

Insiders Place Their Bets

In other news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares of the company's stock, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company's stock.

Institutional Trading of Sarepta Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Capital International Investors increased its holdings in shares of Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company's stock worth $1,057,482,000 after acquiring an additional 2,437,855 shares during the last quarter. Norges Bank bought a new position in Sarepta Therapeutics during the fourth quarter worth $126,315,000. Wellington Management Group LLP boosted its position in Sarepta Therapeutics by 32.3% during the third quarter. Wellington Management Group LLP now owns 2,726,613 shares of the biotechnology company's stock worth $340,527,000 after purchasing an additional 665,087 shares during the period. Erste Asset Management GmbH acquired a new position in shares of Sarepta Therapeutics in the third quarter valued at $79,425,000. Finally, Janus Henderson Group PLC raised its position in shares of Sarepta Therapeutics by 14.2% in the third quarter. Janus Henderson Group PLC now owns 4,358,511 shares of the biotechnology company's stock valued at $544,408,000 after purchasing an additional 543,143 shares during the period. Institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.